In the past week, TSHA stock has gone down by -11.43%, with a monthly gain of 64.89% and a quarterly surge of 304.49%. The volatility ratio for the week is 12.54%, and the volatility levels for the last 30 days are 14.68% for Taysha Gene Therapies Inc. The simple moving average for the last 20 days is 4.69% for TSHA stock, with a simple moving average of 137.07% for the last 200 days.
Is It Worth Investing in Taysha Gene Therapies Inc. (NASDAQ: TSHA) Right Now?
Moreover, the 36-month beta value for TSHA is -0.02. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price recommended by analysts for Taysha Gene Therapies Inc. (TSHA) is $5.72, which is $2.62 above the current market price. The public float for TSHA is 144.73M and currently, short sellers hold a 5.08% of that float. On September 19, 2023, TSHA’s average trading volume was 4.81M shares.
TSHA) stock’s latest price update
Taysha Gene Therapies Inc. (NASDAQ: TSHA) has seen a decline in its stock price by -5.78 in relation to its previous close of 3.29. However, the company has experienced a -11.43% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-09-05 that Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TSHA’s 50-day simple moving average broke out above its 200-day moving average; this is known as a “golden cross.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with Jefferies repeating the rating for TSHA by listing it as a “Hold.” The predicted price for TSHA in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 01, 2023 of the current year 2023.
TSHA Trading at 81.85% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.31% of loss for the given period.
Volatility was left at 14.68%, however, over the last 30 days, the volatility rate increased by 12.54%, as shares surge +61.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +384.38% upper at present.
During the last 5 trading sessions, TSHA fell by -11.43%, which changed the moving average for the period of 200-days by +43.52% in comparison to the 20-day moving average, which settled at $3.02. In addition, Taysha Gene Therapies Inc. saw 37.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Alam Kamran, who sale 33,000 shares at the price of $2.33 back on Aug 24. After this action, Alam Kamran now owns 258,042 shares of Taysha Gene Therapies Inc., valued at $76,890 using the latest closing price.
Manning Paul B, the 10% Owner of Taysha Gene Therapies Inc., purchase 16,466,667 shares at $0.90 during a trade that took place back on Aug 16, which means that Manning Paul B is holding 16,466,667 shares at $14,820,000 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -5037.05 for the present operating margin
- +0.60 for the gross margin
The net margin for Taysha Gene Therapies Inc. stands at -6635.25. The total capital return value is set at -114.91, while invested capital returns managed to touch -152.42.
Based on Taysha Gene Therapies Inc. (TSHA), the company’s capital structure generated 6,314.86 points at debt to equity in total, while total debt to capital is 98.44. Total debt to assets is 46.59, with long-term debt to equity ratio resting at 6,154.58. Finally, the long-term debt to capital ratio is 95.94.
When we switch over and look at the enterprise to sales, we see a ratio of 61.14, with the company’s debt to enterprise value settled at 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To wrap up, the performance of Taysha Gene Therapies Inc. (TSHA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
